Breaking News, Financial News

Financial Report: Hospira 1Q

Specialty Injectable Pharmaceuticals up 13%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hospira   1Q Revenues: $1.2 billion (+12%) 1Q Earnings: $75.6 million (+11%) Comments: Growth in the quarter was driven by sales of Specialty Injectable Pharmaceuticals (SIP) in the U.S. (+17% to $665.5 million), as well as biosimilar sales in the Europe, Middle East and Africa (EMEA) segment. Global SIP sales were $808.5 million, up 13%. Sales growth offset the decline Precedex, which lost market exclusivity in 2H14....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters